Journal: Lancet (London, England)
Article Title: Complement in human disease: approved and up-and-coming therapeutics
doi: 10.1016/S0140-6736(23)01524-6
Figure Lengend Snippet: Up-and-coming anti-complement therapies. Several current complement drugs (that are not authorized for any indications yet) with Orphan Status or Designation or with Breakthrough Therapy Designation. aHUS, atypical haemolytic uremic syndrome; AMD, age-related macular degeneration; C3G, C3 glomerulopathy; COVID-19, coronavirus disease 2019; IgAN, IgA nephropathy; MG, myasthenia gravis; PNH, paroxysmal nocturnal haemoglobinuria; TA-TMA, stem cell transplant associated (TA) thrombotic microangiopathy (TMA).
Article Snippet: These include, for example, crovalimab , an anti-C5 antibody tested for self-administered subcutaneous dosing in PNH (Roche), 38 the PEGylated aptamer avacincaptad pegol (Iveric Bio), 39 which inhibits C5 processing into C5a/C5b and is under Priority Review with the FDA for eye injection treatment of geographic atrophy (GA), as well as novel modalities such as the cyclic peptide C5 inhibitor zilucoplan (RA Pharma), 40 and the recombinant tick-derived small protein nomacopan (Akari Therapeutics), 41 which blocks both C5 activation by the C5 convertase and leukotriene B4 activity.
Techniques: Activation Assay, Activity Assay, Recombinant